Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 297

1.

Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.

Yoshida T, Ishii G, Goto K, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Nagai K, Ohe Y, Ochiai A.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1691-700. doi: 10.1007/s00432-013-1495-0. Epub 2013 Aug 22.

PMID:
23974272
[PubMed - indexed for MEDLINE]
2.

Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H, Haga H.

J Thorac Oncol. 2013 Jan;8(1):52-61. doi: 10.1097/JTO.0b013e3182769aa8.

PMID:
23242438
[PubMed - indexed for MEDLINE]
3.

Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.

Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D, John T.

J Thorac Oncol. 2013 Apr;8(4):461-8. doi: 10.1097/JTO.0b013e3182828fb8.

PMID:
23486266
[PubMed - indexed for MEDLINE]
4.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS.

Lung Cancer. 2012 Sep;77(3):556-60. doi: 10.1016/j.lungcan.2012.05.092. Epub 2012 Jun 5.

PMID:
22677429
[PubMed - indexed for MEDLINE]
5.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.

Cho SH, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.

Cancer Chemother Pharmacol. 2012 Aug;70(2):315-20. doi: 10.1007/s00280-012-1876-0. Epub 2012 Jul 4.

PMID:
22760226
[PubMed - indexed for MEDLINE]
6.

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.

Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.

J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929.

PMID:
23591159
[PubMed - indexed for MEDLINE]
7.

Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.

Fukihara J, Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Matsuda T, Yokoyama T, Hasegawa Y.

Oncology. 2014;86(2):86-93. doi: 10.1159/000357129. Epub 2014 Jan 18.

PMID:
24457318
[PubMed - indexed for MEDLINE]
8.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

PMID:
22982650
[PubMed - indexed for MEDLINE]
9.

Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.

Zakowski MF, Hussain S, Pao W, Ladanyi M, Ginsberg MS, Heelan R, Miller VA, Rusch VW, Kris MG.

Arch Pathol Lab Med. 2009 Mar;133(3):470-7. doi: 10.1043/1543-2165-133.3.470.

PMID:
19260752
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

[Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].

He P, Wang Y, Yang S, Yu S, Wang Z, Li J, Wang B, Hao X, Wang H, Hu X, Zhang X, Shi Y.

Zhongguo Fei Ai Za Zhi. 2013 Oct 20;16(10):529-34. doi: 10.3779/j.issn.1009-3419.2013.10.06. Chinese.

PMID:
24113006
[PubMed - indexed for MEDLINE]
Free Article
11.

[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].

Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H, Liu X.

Zhongguo Fei Ai Za Zhi. 2012 May;15(5):299-304. doi: 10.3779/j.issn.1009-3419.2012.05.09. Chinese.

PMID:
22613337
[PubMed - indexed for MEDLINE]
Free Article
12.

[Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations].

Zhu X, Liang L, Liu C, Yin W, Chen S, Cao B.

Zhongguo Fei Ai Za Zhi. 2014 Feb;17(2):155-62. doi: 10.3779/j.issn.1009-3419.2014.02.15. Chinese.

PMID:
24581168
[PubMed - indexed for MEDLINE]
Free Article
13.

Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients.

Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y.

Med Oncol. 2013;30(3):645. doi: 10.1007/s12032-013-0645-1. Epub 2013 Jun 25.

PMID:
23797772
[PubMed - indexed for MEDLINE]
14.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

PMID:
21670455
[PubMed - indexed for MEDLINE]
Free Article
15.

Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.

Wu SG, Chang YL, Hsu YC, Wu JY, Yang CH, Yu CJ, Tsai MF, Shih JY, Yang PC.

Oncologist. 2008 Dec;13(12):1276-84. doi: 10.1634/theoncologist.2008-0093. Epub 2008 Dec 5.

PMID:
19060236
[PubMed - indexed for MEDLINE]
Free Article
16.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
[PubMed - indexed for MEDLINE]
Free Article
17.

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).

Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A.

Clin Transl Oncol. 2011 Nov;13(11):812-8. doi: 10.1007/s12094-011-0739-1.

PMID:
22082647
[PubMed - indexed for MEDLINE]
18.

How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?

Hata A, Katakami N, Yoshioka H, Kunimasa K, Fujita S, Kaji R, Notohara K, Imai Y, Tachikawa R, Tomii K, Korogi Y, Iwasaku M, Nishiyama A, Ishida T.

J Thorac Oncol. 2013 Jan;8(1):89-95. doi: 10.1097/JTO.0b013e31827690b5.

PMID:
23242440
[PubMed - indexed for MEDLINE]
19.

Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes.

Lee HJ, Kim YT, Kang CH, Zhao B, Tan Y, Schwartz LH, Persigehl T, Jeon YK, Chung DH.

Radiology. 2013 Jul;268(1):254-64. doi: 10.1148/radiol.13112553. Epub 2013 Mar 6.

PMID:
23468578
[PubMed - indexed for MEDLINE]
20.

Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC.

Clin Cancer Res. 2011 Jun 1;17(11):3812-21. doi: 10.1158/1078-0432.CCR-10-3408. Epub 2011 Apr 29.

PMID:
21531810
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk